WT1 and acute myeloid leukemia: NTLA-5001 is an investigational CRISPR/Cas9-engineered T-cell receptor (TCR)-T cell therapy in development for the treatment of all genetic subtypes of acute myeloid leukemia (AML) using a WT1-targeting TCR.